Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 1,101–1,200 of 3,116
From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management?
Koufakis, T., & Busetto, L. (2025) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2025.102589 · Cited by 10
Kachmar, M., Corpodean, F., Popiv, I., LaPenna, K. B., Danos, D., Cook, M. W., Saunders, B. A., Domercant, J. J., Albaugh, V. L., & Schauer, P. R. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01798-2 · Cited by 6
Hathorn, B., Haykowsky, M. J., Almandoz, J. P., Pandey, A., Sarma, S., Hearon, C. M., Babb, T. G., Balmain, B. N., Fu, Q., Zaha, V. G., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.015 · Cited by 9
Obesity in Cardiovascular Disease Prevention and Treatment---A Topic Getting “Heavier” as We Speak
Lavie, C. J., Hegele, R. A., Poirier, P., & Thompson, J. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.011 · Cited by 11
Cross, L. V. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae273 · Cited by 8
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
Gries, J. J., Chen, B., Bansal, M. B., Rodríguez, M., Alqahtani, S. A., Brennan, P., Lang, C. C., Tang, W. H. W., Lazarus, J. V., & Krittanawong, C. (2025) · Communications Medicine · doi:10.1038/s43856-025-00951-2 · Cited by 8
Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss
Sforzo, G. A., Gordon, N. F., Peeke, P. M., & Moore, M. A. (2024) · American Journal of Lifestyle Medicine · doi:10.1177/15598276241302273 · Cited by 8
Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease
Thapa, R., Lara-Breitinger, K. M., López-Jiménez, F. A., Shama, N., Egbe, A. C., Miranda, W. R., Connolly, H. M., Jain, C. C., Jokhadar, M., Kosec, A. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101674 · Cited by 6
Efectos cardiometabólicos de la pérdida de peso
Genua, I., Sardà, H., & Pérez, A. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.102953 · Cited by 6
Obesity and Acute Pulmonary Embolism
Zuin, M., Piazza, G., Barco, S., Bertoletti, L., Ciurzyński, M., Skoro‐Sajer, N., Kurzyna, M., Mouratoglou, S., Hobohm, L., & Klok, F. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1504 · Cited by 9
Rinaldi, R., Kunadian, V., Crea, F., & Montone, R. A. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.03.001 · Cited by 19
First in class, best in class or a wild card: who will dominate the anti-obesity medication market?
Collins, E., Beattie, A., Ramagopalan, S. V., et al. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0044 · Cited by 5
A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy
Eliopoulos, A. G., Gkouskou, K. K., Tsioufis, K. P., & Sanoudou, D. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1524125 · Cited by 8
Glucagon-like Peptide-1 Receptor Agonist Use in Hospital: A Multicentre Observational Study
Ray, P., Moggridge, J. A., Weisman, A., Tadrous, M., Drucker, D. J., Perkins, B. A., & Fralick, M. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.10.011 · Cited by 5
Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults
Hennessy, S. S., Penko, J. M., Bellows, B. K., Coxson, P. G., Boylan, R. D., Sims, K. D., Beatty, A. L., Inoue, K., Shi, I., Decker, S. R. D. R., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5243 · Cited by 9
Salerno, E., Fumarulo, I., Garramone, B., Vaccarella, M., Ierardi, C., Burzotta, F., & Aspromonte, N. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103213 · Cited by 6
Hviid, M. E. B., Christoffersen, L. A. N., Klausen, M. K., Brodersen, T., Pedersen, O. B., Ostrowski, S. R., Larsen, M. H., Kongstad, M., Jensen, M. E., Vilsbøll, T., et al. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70110 · Cited by 8
Candelaria, D., Redfern, J., Zecchin, R. P., Brown, R., Freene, N., Fukumori, S., Gallagher, R. D., Gauci, S., Goodman, A., Hicks, D., et al. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.05.008 · Cited by 10
Liu, Y., Duan, X., Hua, P., Wu, S., & Liu, X. (2024) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_693_23 · Cited by 6
Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices
ELAD, B., Lee, C., Rahman, A., Rzechorzek, W., DeFilippis, E. M., Lotan, D., Moeller, C. M., Valledor, A. F., Rahman, S., Baranowska, J., et al. (2025) · Artificial Organs · doi:10.1111/aor.14942 · Cited by 6
Kobe, E. A., Thakkar, A., Matai, S., Akkaya, E., Pagidipati, N. J., McGarrah, R. W., Bloomfield, G. S., & Shah, N. P. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100888 · Cited by 9
Singh, A., & Bruemmer, D. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100867 · Cited by 7
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Muir, K. C., Harris, D. D., Stone, C., Kanuparthy, M., Broadwin, M., Hamze, J., & Sellke, F. W. (2025) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2025.04.017 · Cited by 6
To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists
Guevara, L. R. H., Beam, W. B., & Pasternak, J. J. (2024) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000985 · Cited by 5
Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes
Patoulias, D., Popovic, D. S., Koufakis, T., Stavropoulos, K., & Doumas, M. N. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.12.022 · Cited by 5
Seeing the Truth About Double Blinding
Redelmeier, D. A., & Zipursky, J. S. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08887-4 · Cited by 7
Muthalaly, R. G., Abrahams, T., Nerlekar, N., Nelson, A. J., Tan, S., Chan, J., Phan, T. G., Ma, H., & Nicholls, S. J. (2024) · European Stroke Journal · doi:10.1177/23969873241231702 · Cited by 7
A System-Based Review on Effects of Glucagon-Like Peptide-1 Receptor Agonists: Benefits vs Risks
Fadel, L. P., Thao, G., Chitre, T., Rojas, E. D., Fricko, M. N., Domingo, V., Budginas, B., Guerrero, L. C., Ghatas, M., Arani, N. T., et al. (2025) · Cureus · doi:10.7759/cureus.78575 · Cited by 12
Schooling, C. M., Yang, G., Soliman, G. A., & Leung, G. M. (2025) · Life · doi:10.3390/life15020253 · Cited by 9
Velasco, M. Á. P., Trenas, A., Bernal-López, M. R., de Lucas, M. D. G., Gómez‐Huelgas, R., & Perez-Belmonte, L. M. (2024) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.12.008 · Cited by 5
Grancini, V., Cogliati, I., Alicandro, G., Oliverio, A., Benedetto, C. D., Gaglio, A., Lampertico, P., Resi, V., & Orsi, E. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1586941 · Cited by 10
Nicolau, J., Nadal, A., Sanchís, P., Pujol, A., Tamayo, M. I., Nadal, C., & Masmiquel, L. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.106941 · Cited by 5
Bril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 7
Silverii, G. A., Monami, M., Rotella, F., Luca, M. D., Viozzi, T., Barazzoni, R., Buscemi, S., Busetto, L., Sbraccia, P., & Mannucci, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70202 · Cited by 6
Jiang, P., Zeng, Y., Yang, W. Y., Li, L., Zhou, L., Xiao, L., Li, Y., Gu, B., Li, X., Li, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116485 · Cited by 5
Salama, L., & Sinn, L. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf053 · Cited by 9
Metzner, A., Willems, S., Borof, K., Breithardt, G., Camm, A. J., Crijns, H. J. G. M., Eckardt, L., Fabritz, L., Geßler, N., Goette, A., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.2374 · Cited by 5
A treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT ‐5 trial
le Roux, C. W., Busetto, L., Aronne, L. J., Horn, D. B., Dimitriadis, G. K., Falcón, B. L., García‐Pérez, L., Valderas, E. G., Gibble, T. H., Şenyücel, Ç., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70531 · Cited by 5
“49 With the emergence of new and more efficacious OMMs with reported positive long-term outcomes 50 and ongoing outcome trials, 51,52 the TtT approach may clarify goals and expectations.”
Excess and Dysfunctional Fat as a Primary Driver of Heart Failure With Preserved Ejection Fraction
Packer, M., Ho, J. E., Petrie, M. C., Schiattarella, G. G., Butler, J., Lam, C. S. P., Vaduganathan, M., Zannad, F. M., & Borlaug, B. A. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103046 · Cited by 10
Trenas, A., Velasco, M. Á. P., Bernal-López, M. R., Lopez-Carmona, M. D., Gómez‐Doblas, J. J., Martínez-Esteban, M. D., Bouarich, O., García‐Casares, N., Fernández‐García, D., de Lucas, M.-D. G., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.007 · Cited by 6
Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer’s Disease
Crook, H., & Edison, P. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240730 · Cited by 6
Sclafani, M., Spartera, M., Esmati, Y., Baynham-Williams, O., Khan, I., Brigoli, M., Krasopoulos, C., Ormerod, J., Tang, P., Rider, O. J., et al. (2026) · JAMA · doi:10.1001/jama.2026.5787 · Cited by 12
Nguyen, N., & Michelis, K. C. (2025) · US Cardiology Review · doi:10.15420/usc.2024.34 · Cited by 7
Fawzy, A. M., Bisson, A., Lochon, L., Lenormand, T., Lip, G. Y. H., & Fauchier, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041044 · Cited by 5
Sotagliflozin: Two Birds with One Stone?
Requena-Ibáñez, J. A., Kindberg, K. M., Santos‐Gallego, C. G., Zafar, M. U., & Badimón, J. J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07723-z · Cited by 7
Contemporary management of advanced chronic kidney disease: An evidence-based review
Baker, L. W., Ovincy, C., Souvalian, L., Hickson, L. J., & Chebib, F. T. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106557 · Cited by 9
GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched study
Tentolouris, A., Ntanasis‐Stathopoulos, I., Filippatos, C., Terpos, E., Kastritis, E., Duque, E. R., Dimopoulos, M. A., Gavriatopoulou, M., & Briasoulis, Α. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70140 · Cited by 8
“37 In line with this evidence, current guidelines from the American Diabetes Association recommend GLP-1 RAs for individuals with type 2 DM and established CV disease.”
The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management
Suter, B., Rhodes, A. L., Bigeh, A., Frommeyer, T. C., & Mehta, L. S. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00761-0 · Cited by 8
Xu, B., Gaynor-Sodeifi, K., & Kundel, V. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03312-6 · Cited by 6
A primer on the pleiotropic endocrine fibroblast growth factor FGF19/FGF15
Bouju, A., Nusse, R., & Wu, P. V. (2024) · Differentiation · doi:10.1016/j.diff.2024.100816 · Cited by 10
Schechter, M., Fishkin, A., Mosenzon, O., Sehtman-Shachar, D. R., Cukierman‐Yaffe, T., Leibowitz, G., & Aharon‐Hananel, G. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02962-8 · Cited by 10
“The results of this large trial will provide important, and hopefully conclusive, evidence on the potential disease-modifying effects of semaglutide in people already diagnosed with Alzheimer's disease [43].”
Jones, K. L., Marathe, C. S., Wu, T., Rayner, C. K., Nauck, M. A., & Horowitz, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15631 · Cited by 5
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Steinacher, E., Hammer, A., Baumer, U., Hofer, F., Kazem, N., Lenz, M. W., Leutner, M., Lang, I. M., Hengstenberg, C., Sulzgruber, P., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf023 · Cited by 5
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Yehualashet, E., Mazroua, M. S., Narvaez, E., Jarosinski, M. C., Liang, N. L., Madigan, M. C., Chaer, R. A., & Sridharan, N. D. (2025) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2025.08.013 · Cited by 5
Cozma, D. C., Văcărescu, C., & Stoicescu, C. I. (2025) · Biomedicines · doi:10.3390/biomedicines13123079 · Cited by 6
“…[1] Clinical trials have demonstrated that GLP-1 RAs achieve substantial improvements in weight reduction, glycemic control, and cardiovascular outcomes, yet real-world persistence often declines over time, driven by cost, side effects, and psychological adaptation to blunted food reward [2–4].”
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
Mahesh, R., Wong, D., Anand, V. V., Soh, D. K. E., Low, G. Z., Hao, Y., Chen, Y., Chong, B., Hartanto, A. D., Chen, J. N., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02800-7 · Cited by 6
Sambola, A., Campuzano, R., Castro, A., Goya, M., Coronado, P., Fernández-Olmo, R., Tablado, M. Á. M., Ortiz-Cortés, C., Ortolà, X., Pallarés‐Carratalá, V., et al. (2025) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2025.01.005 · Cited by 10
Holtrop, J. S., Tietbohl, C. K., Perreault, L., Connelly, L., Smith, P. C., & Williams, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1584799 · Cited by 7
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Yan, H., Karthikeyan, H., Fan, W., Yang, Q., & Wong, N. D. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101773 · Cited by 4
Helmink, M. A. G., Peters, S. A. E., Westerink, J., Harris, K., Tillmann, T., Woodward, M., van Sloten, T. T., van der Meer, M. G., Teraa, M., Dorresteijn, J. A. N., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae096 · Cited by 7
Sillassen, C. D. B., Kamp, C. B., Petersen, J. J., Faltermeier, P., Siddiqui, F., Grand, J., Domínguez, H., Frølich, A., Gæde, P., Gluud, C. N., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084190 · Cited by 11
Herges, J. R., Neumiller, J. J., & McCoy, R. G. (2025) · Clinical Diabetes · doi:10.2337/cd24-0115 · Cited by 5
Externalized Inflammasomes in Visceral Fat Sustain Obesity-Related Inflammation
Wissemann, J., Heidenreich, A., Suchanek, D., Koentges, C., Engelmann, J., Jung, M., Karnbrock, L., Marchini, T., Pospisilik, J. A., Seifert, G. J., et al. (2025) · Circulation Research · doi:10.1161/circresaha.125.327146 · Cited by 4
Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease
Verma, S., Catarig, A., Houlind, K. C., Ludvik, B. H., Nordanstig, J., Rasouli, N., Sourij, H., Thomas, S., Nørgaard, S. K., & Bonaca, M. P. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.046 · Cited by 5
Chandra, A. A., Espiche, C., Maliha, M., Virani, S. S., Blumenthal, R. S., Rodríguez, F., Wong, N. D., Gulati, M., Slipczuk, L. N., & Shapiro, M. D. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100919 · Cited by 7
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Oikonomou, E. K., Chan, K., Patel, P., Wahome, E., Dangas, K., Desai, R., Sobirov, I., Khera, R., Petersen, S. E., Pugliese, F., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5116 · Cited by 11
Self-citationLiraglutide in the management of obesity: real world data (Portugal)
Bello, C., Carvalho, I. R., Martins, A., Martins, A. F., Wessling, A., Macedo, D. D., Martins, D., Fernandes, C. C., & do Rosário, F. S. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.24.04161-7 · Cited by 4
Abbas, M. T., Farina, J. M., Ibrahim, O. H., Ahmed, S., Bismee, N. N., Awad, K., Jamal, F., Sheashaa, H., Pereyra, M., Scalia, I. G., et al. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2026.01.003 · Cited by 5
New insights into understanding obesity: from measures to mechanisms
Timpson, N. J., Wade, K. H., Smith, M. L., Goudswaard, L. J., Sattar, N. A., Pournaras, D. J., & Corbin, L. J. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2023-000787 · Cited by 7
AMPK-Mediated Multi-Organ Protective Effects of GLP-1 Receptor Agonists
Wang, X., & Wang, L. (2025) · Health and Metabolism · doi:10.53941/hm.2025.100004 · Cited by 7
Alper, A., Peleg, G., Fagin, A., Shah, P. P., Chowdhury, I. Z., Gonzales, A., & FAILLACE, R. T. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00270-4 · Cited by 7
da Silva, A. M. P., Cardoso, L. J. C., Batista, S., Gonçalves, O. R., Paranhos, T., Teixeira, I. P. S., Guimarães, P. D., Franco, B. E., Cal, H. D. S. R., Salles, J. E. N., et al. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109306 · Cited by 6
Obesity Phenotypes Causally Affect Cardiac MRI Structure and Induced Non-ischaemic Cardiomyopathy
Peng, L., Zeng, T., Quan, E., Pan, S., Li, B., Wen, Z., Xiong, Z., & Zhao, Y. (2025) · Cardiac failure review · doi:10.15420/cfr.2024.26 · Cited by 4
Six Substudies From the Semaglutide Trials
Pagidipati, N. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.038 · Cited by 4
Treating obesity to optimize women’s health outcomes
Rubino, D., & Schon, S. B. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002595 · Cited by 4
Luca, M. D., COHEN, R. V., Belluzzi, A., Navarra, G., Lorenzo, N. D., Petry, T. B. Z., Sbraccia, P., Busetto, L., Buscemi, S., Barazzoni, R., et al. (2026) · Obesity · doi:10.1002/oby.70083 · Cited by 5
“Quite interestingly, the placebo-controlled cardiovascular outcome trial on semaglutide [51] performed in patients affected by overweight/obesity and previous cardiovascular disease reported subgroup analyses for different classes of BMI, showing a significantly lower incidence of major…”
How ‘miracle’ weight-loss drugs will change the world
Reardon, S. (2024) · Nature · doi:10.1038/d41586-024-03589-7 · Cited by 4
Lincoff, A. M., & Ryan, D. H. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad097 · Cited by 4
Self-citationGLP-1 receptor agonists: an emerging tool for obesity-related cancer prevention?
Yarmolinsky, J., & Gunter, M. J. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf212 · Cited by 4
ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum
Luca, L. D., Bilato, C., Navazio, A., Corda, M., Milli, M., Scicchitano, P., Marco, M. D., Riccio, C., Geraci, G., Iacovoni, A., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf071 · Cited by 4
Adeniran, O. F., Nieto, L. M., Amadi, C., Shepherd, K., Kirkpatrick, J., Farah, K., Marwizi, F. M., Alqinai, B., Narvaez, S. I., Mensah, S., et al. (2025) · Obesity · doi:10.1002/oby.70001 · Cited by 6
Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
Natale, F., Luisi, E., Franzese, R., Mollo, N., Solimene, A., Caso, V. M., Corvino, A., Golino, P., & Cimmino, G. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050145 · Cited by 8
Voorhout, L., Verburg, A., Pisters, R., ten Berg, J. M., & Hemels, M. E. W. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2603066 · Cited by 5
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
Heerspink, H. J. L., van Raalte, D. H., Bjornstad, P., Bunck, M. C. M., Wu, P., Tunali, I., Miličević, Z., & Koeneman, L. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf230 · Cited by 9
“Specifically, GLP-1 RAs have consistently been shown to confer cardiovascular protection in individuals with T2D and/or obesity [4 –6 ].”
Batista, J. L., Makuvire, T. T., Davis, J. D., & Carbone, S. (2025) · US Cardiology Review · doi:10.15420/usc.2024.44 · Cited by 4
An analysis of national news coverage of semaglutide for weight loss
Gionfriddo, M. R., Owens, K. M., Banks, H., Sherigar, A., & Covvey, J. R. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102297 · Cited by 7
Lo, J., Melhorn, S. J., Kee, S., Olerich, K. L. W., Huang, A., Yeum, D., Beiser, A., Seshadri, S. S., DeCarli, C. S., & Schur, E. A. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039463 · Cited by 5
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Hurwitz, M., Agboola, O. J., Gami, A., Williams, M. S., Virani, S. S., Sharma, G. V., & Patel, J. (2025) · US Cardiology Review · doi:10.15420/usc.2024.33 · Cited by 10
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
Bombonato, M., Beccuti, G., Benso, A. S., Giannone, B., Bertaina, S., Broglio, F., & Bioletto, F. (2025) · HORMONES · doi:10.1007/s42000-025-00632-8 · Cited by 7
Weight maintenance after discontinuation of GLP-1 therapies
Moiz, A., Filion, K. B., Knäuper, B., Tsoukas, M. A., Brazeau, A.-S., Zolotarova, T., Lelièvre, A., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103992 · Cited by 7
“29 In addition, the SURPASS-CVOT trial (tirze-patide) showed comparable cardiovascular outcomes with dual GLP-1/GIP receptor agonism relative to established GLP-1 RAs (dulaglutide).”
Dosda, A., Fauchier, G., Sabbah, N., Fauchier, L., Lecomte, T., & Ducluzeau, P. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101734 · Cited by 7
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
